Steroidal mineralocorticoid receptor antagonists (MRAs) lower mortality in patients with heart failure and reduced ejection fraction (HFrEF), but more data are needed about nonsteroidal MRAs like finerenone for patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF).

During ESC Congress 2024, initial results from FINEARTS-HF found finerenone lowered the total risk of worsening HF events and death from cardiovascular causes among roughly 6,000 patients with HFmrEF and HFpEF from 64 sites in 37 countries compared with placebo. Three new studies presented at HFSA 2024 and simultaneously published in JACC, dive further into the FINEARTS-HF data to explore the impact of finerenone on quality of life, time to benefit, and in patients with HFmrEF and HFpEF who have also experienced a worsening HF event.

Patients with chronic kidney disease (CKD) whose systolic blood pressure (SBP), LDL-C and fasting blood glucose (FBG) were controlled to target levels experienced a similar number of primary outcome events as patients without CKD, according to a new study published in JACC.

Treatment with aficamten in patients with obstructive hypertrophic cardiomyopathy (oHCM) was associated with broad clinical efficacy across multiple outcome domains, including rapid and sustained decreases in outflow gradients, meaningful improvements in functional class and quality of life, enhanced exercise capacity, and significant reductions in N-terminal pro–B-type natriuretic peptide (NT-proBNP) and hs-troponin concentrations, according to new findings from the SEQUOIA-HCM trial presented as part of HFSA 2024 and simultaneously published in JACC.

Not only do former smokers have lower risk of atrial fibrillation (AFib) than current smokers, but patients who quit smoking may reduce their AFib risk while doing so, according to a longitudinal cohort study utilizing UK Biobank data, published in JACC: Clinical Electrophysiology.

Urinary levels of non-essential (i.e., cadmium, tungsten, uranium) and essential metals (i.e., cobalt, copper, zinc) are associated with increased coronary artery calcification (CAC) and are comparable to traditional cardiovascular disease risk factors like smoking and diabetes, according to results from the Multi-Ethnic Study of Atherosclerosis (MESA) published in JACC.

In patients with type 2 diabetes (T2D) and cancer who had been treated with potentially cardiotoxic antineoplastic therapies, the use of SGLT2 inhibitors at baseline was associated with a significantly lower risk of cancer therapy-related cardiac dysfunction (CTRCD), according to a study presented during the Global Cardio-Oncology Summit (GCOS), held in Minneapolis, MN, and simultaneously published in JACC: CardioOncology.